Antibody Therapeutics for Life

History

  • 2018
    • 01.16
    • Clinical Research Collaboration for Combo Trials
    • 03.08
    • ODD approval of TTAC-0001 for rGBM
    • 09.17
    • Biologics Award
    • 09.28
    • Approval of TTAC-0001 Phase II IND for Avastine
      refractory rGBM Patients
    • 10.31
    • Orphan drug development appointed
    • 11.21
    • KOSDAQ listed
    • 12
    • TTAC-0001 + Keytruda combo phase 1b/2 for both
      recurrent Glioblastoma multiforme and metastatic
      Triple Negative Breast Cancer trials are open to
      recruit patients at multicenter in Australia
  • 2017
    • 04.13
    • Commendation from KHIDI
    • 06.
    • Completion of TTAC-0001 Phase IIa for rGBM Patients
  • 2016
    • 02.10
    • Start of TTAC-0001 Phase IIa for rGBM Patients
    • 06.27
    • Commendation from KFDS
  • 2015
    • 09.09
    • Nominated as Korea Brain Power Company in 2015
    • 10.15
    • TTAC-0001 Achieved an excellence in national R&D
      Selected for 100 selections as the best
      accomplishments Awarded from Ministry of Science
      and ICT
  • 2014
    • 03.04
    • Selected as INNOBIZ company
    • 03.11
    • Out-Licensing of TTAC-0001
    • 05.26
    • Korea Eureka Day Award 2014
    • 06.15
    • Tech-Connect National Innovation Award
    • 07.16
    • Out-Licensing of PMC-001
    • 10.29
    • Out-Licensing of TTAC-0001
    • 11.13
    • Award from the Minister from KMTIE
      - Distinguished Industrial
      Engineer (CEO)
      - Technology Commercialization
      (CFO)
    • 12.17
    • Health and Medical Technology
      Development Business Award
      (CEO)
    • 12.25
    • Out-Licensing PMC-001
  • 2013
    • 03.22
    • Out-Licensed of 1E4 mAb
    • 09.25
    • Completion of TTAC-0001 Phase 1
    • 10.23
    • Ministry of Education Award
  • 2012
    • 04.25
    • Pharma -Idol Award from 7th Annual
      China Pharmaceutical R&D Summit Conference
    • 11.01
    • Research collaboration with Sanofi-Aventis
  • 2011
    • 07.25
    • TTAC-0001 IND approved
    • 09.23
    • Green Technology Citification
    • 11.08
    • Start of TTAC-0001 Phase 1
  • 2009
    • 03.13
    • Certificated as venture business
    • 09.22
    • Designation of foreign investment company
    • 12.17
    • R&D Center affiliated
  • 2008
    • 09.03
    • Foundation of PharmAbcine Inc.
    • 10.09
    • Grand Prix from 1st GATE Project